- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00156884
A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
January 18, 2012 updated by: Alberta Health services
A Randomized Phase II Trial of Strontium-89 With or Without Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostate cancer.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostate cancer.
Study Type
Interventional
Enrollment (Anticipated)
58
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Tom Baker Cancer Centre
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- BC Cancer Agency
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- adenocarcinoma of the prostate
- life expectancy > 3 months,
- symptomatic from bone metastases
- radiologic evidence of metastatic bone disease
- stable level of pain control
- >18 years
- ability to complete assessments
- prior treatment (chemo) > 4 weeks previous
- discontinued anti-androgens for > 4 weeks
Exclusion Criteria:
- prior strontium therapy
- previous hemibody RT within 6 weeks
- previous cytotoxic chemotherapy within 4 weeks
- use of bisphosphonate medications within 4 weeks
- change in steroid dose within 4 weeks
- active uncontrolled infection
- impending or present spinal cord compression
- significant neurological disorder
- impending pathological fracture
- severe urinary incontinence
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Palliative pain response
|
analgesic response
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Bernie Eigl, MD, Alberta Cancerboard
- Principal Investigator: Jackson Wu, Alberta Cancerboard
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2003
Primary Completion (Actual)
May 1, 2008
Study Completion (Actual)
May 1, 2008
Study Registration Dates
First Submitted
September 8, 2005
First Submitted That Met QC Criteria
September 8, 2005
First Posted (Estimate)
September 12, 2005
Study Record Updates
Last Update Posted (Estimate)
January 19, 2012
Last Update Submitted That Met QC Criteria
January 18, 2012
Last Verified
August 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GUPPS2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bone Metastases
-
University of CalgaryNot yet recruitingBone Metastases | Spine Metastases | Bone LesionCanada
-
Luye Pharma Group Ltd.RecruitingBone Metastases From Solid TumorsChina
-
Shanghai JMT-Bio Inc.CompletedBone Metastases From Solid TumorsChina
-
Varian, a Siemens Healthineers CompanyRecruitingBone Metastases in the ThoraxUnited States
-
Ottawa Hospital Research InstituteWithdrawn
-
UMC UtrechtCompletedBone Metastases | Spinal MetastasesNetherlands
-
University of Roma La SapienzaCompletedBone Metastases | Secondary Bone CancerItaly
-
Shanghai JMT-Bio Inc.Not yet recruitingImaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors
-
Heidelberg UniversityCompletedVertebral Bony MetastasesGermany
-
Centre Henri BecquerelUnknown
Clinical Trials on cisplatin
-
West China Second University HospitalRecruitingNeoadjuvant Chemotherapy | Epithelial Carcinoma, OvarianChina
-
Insmed IncorporatedCompletedOsteosarcoma MetastaticUnited States
-
Samsung Medical CenterUnknownNasophayngeal Carcinoma Between Stage II and IVbKorea, Republic of
-
Privo TechnologiesNational Cancer Institute (NCI)CompletedOral Squamous Cell CarcinomaUnited States
-
Taiho Oncology, Inc.Quintiles, Inc.Completed
-
Cedars-Sinai Medical CenterRecruitingHPV Positive Oropharyngeal Squamous Cell CarcinomaUnited States
-
Korea Cancer Center HospitalCompletedCervical CancersKorea, Republic of
-
Lawson Health Research InstituteRecruitingLocally Advanced Head and Neck Squamous Cell CarcinomaCanada
-
Sun Yat-sen UniversityActive, not recruitingNasopharyngeal CarcinomaChina
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...CompletedHead and Neck Squamous Cell CarcinomaBangladesh